التفاصيل البيبلوغرافية
| العنوان: |
Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia |
| المؤلفون: |
Copelan, Edward A.1 copelae@ccf.org, Crilley, Pamela Ann2, Szer, Jeffrey3, Dodds, Anthony J.4, Stevenson, Dustin5, Phillips, Gary6, Elder, Patrick7, Nivison-Smith, Ian4, Avalos, Belinda R.7, Penza, Sam7, Topolsky, David2, Sobecks, Ronald1, Kalaycio, Matt1, Bolwell, Brian J.1 |
| المصدر: |
Biology of Blood & Marrow Transplantation. Jul2009, Vol. 15 Issue 7, p851-855. 5p. |
| مصطلحات موضوعية: |
*MORTALITY, *DISEASE relapse, *HLA histocompatibility antigens, *STEM cell transplantation, *DRUG therapy, *HEMATOPOIETIC stem cells, *TREATMENT of chronic myeloid leukemia |
| مستخلص: |
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for chronic myelogenous leukemia (CML). Failure, because of relapse or nonrelapse mortality (NRM), generally occurs within 3 years of transplantation, but large studies with long-term follow-up are limited. We present mature results in 335 patients with CML who underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings following busulfan and cyclophosphamide (BU/Cy2). Two hundred twenty-nine were in chronic phase (CP) and 106 in accelerated or blastic phase at transplantation. Median follow-up exceeded 14 years. The estimated probability of 18-year leukemia-free survival (LFS) for CP patients was 55.6% and for those beyond CP, 10.5%. Of 182 patients who survived leukemia-free at 3 years, the estimated probability of LFS at 18 years was 61.9%. Late relapse (P = .039) and late NRM (P = .008) occurred at higher rates in patients beyond CP at transplantation. There was no plateau in LFS. [Copyright &y& Elsevier] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder